Skip to main content
TipRanks
Go Ultimate75% OFF

Cel-Sci (LSR) Stock Price & Analysis

0 Followers

LSR Stock Chart & Stats

€1.54€0.37(31.62%)
At close: 5:30 PM GMT+1
€1.5€2€2.5Sep 9Oct 5Oct 27Nov 3Nov 16
Day’s Range
EUR 1.15 - EUR 1.54
52-Week Range
EUR 0.76 - EUR 6.35
Previous Close
EUR 1.17
Volume
N/A
Average Volume (3M)
108
Market Cap
EUR 20.43M
Enterprise Value
EUR 13.97M
Total Cash (Recent Filing)
EUR 6.53M
Total Debt (Recent Filing)
EUR 7.89M
Price to Earnings (P/E)
―
Beta
1.97
Next Earnings
Dec 23, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Immunotherapy Focus

CEL-SCI has a focused biotechnology strategy centered on immune-system modulation, with Multikine as its core development program. If clinical development succeeds, this specialized platform could support a differentiated position in cancer treatment and create long-term commercial opportunity.

CDMO Operations

The CDMO segment provides an operating capability beyond the internal drug pipeline and gives the company experience in biologics development and manufacturing. This diversification could support strategic relevance and potentially broaden future revenue sources if the service business scales.

Historically Moderate Leverage

Historical leverage was generally moderate and shareholders’ equity remained positive, indicating that the company had not previously relied on excessive debt relative to its capital base. That balance-sheet profile can provide more flexibility than highly leveraged development-stage peers.

Bears Say

No Commercial Revenue

Zero reported revenue confirms that CEL-SCI has not yet demonstrated a commercial sales base. The business therefore remains dependent on successful development and commercialization of its programs, leaving revenue visibility, scalability, and operating self-sufficiency unproven.

Persistent Losses And Cash Burn

Consistently negative operating and free cash flow means the company is not currently self-funding its operations. Continued losses and annual cash burn can require additional financing over time, potentially limiting strategic flexibility and increasing dependence on capital markets.

Balance-Sheet Volatility

The sharp TTM increase in reported debt and the accompanying expansion in assets and equity represent a major departure from historical levels. This discontinuity raises uncertainty around balance-sheet stability and makes future leverage, capital efficiency, and financial risk harder to assess.

Cel-Sci News

LSR FAQ

What was Cel-Sci’s price range in the past 12 months?
Cel-Sci lowest stock price was €0.76 and its highest was €6.35 in the past 12 months.
What is Cel-Sci’s market cap?
Cel-Sci’s market cap is €20.43M.
When is Cel-Sci’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cel-Sci’s earnings last quarter?
Cel-Sci released its earnings results on Aug 17, 2026. The company reported -€0.428 earnings per share for the quarter.
Is Cel-Sci overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Cel-Sci pay dividends?
Cel-Sci does not currently pay dividends.
What is Cel-Sci’s EPS estimate?
Cel-Sci’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci have?
Cel-Sci has 17,588,987 shares outstanding.
What happened to Cel-Sci’s price movement after its last earnings report?
Cel-Sci reported an EPS of -€0.428 in its last earnings report. Following the earnings report the stock price went up 5.042%.
Which hedge fund is a major shareholder of Cel-Sci?
Currently, no hedge funds are holding shares in DE:LSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology